Krystal Biotech Receives $700K Equity-Based Award to Develop Gene Therapy for DEB – Epidermolysis Bullosa News
Epidermolysis Bullosa News |
Krystal Biotech Receives $700K Equity-Based Award to Develop Gene Therapy for DEB
Epidermolysis Bullosa News “Our lead product candidate KB103, based on our proprietary gene therapy platform, is designed to be an 'off-the-shelf' topical product to treat dystrophic epidermolysis bullosa (DEB). We currently expect to file an Investigational New Drug Application … |
